Skip to main content

Table 5 Associations and effects of cancer-related fatigue on PRO instruments

From: Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy

PRO Instrument

Baseline (n = 89)

Longitudinal phase1 (n = 38)

FACIT-Fatigue

β

95% CI

Wald Chi-square

*p

Time points

FACIT-Fatigue

Model Effects Test

Score < 34

Score ≥ 34

Lower

Upper

Score < 34

Score ≥ 34

Effects

Df

**p

HADS-A

10.94 ± 0.98a

7.16 ± 0.86b

-3.779

-5.498

-2.059

18.546

 < 0.001

  

8.21 ± 1.11a

6.57 ± 0.89b

   
        

T0

9.33 ± 1.15a

10.43 ± 1.25

8.22 ± 1.17a

Time points

2

0.035

       

T1

6.91 ± 0.96b

7.56 ± 1.22

6.26 ± 0.90b

FACIT-Fatigue

1

0.028

       

T2

5.94 ± 1.38a,b

6.63 ± 1.72

5.25 ± 1.31a,b

Interaction2

2

0.602

HADS-D

10.15 ± 1.00a

5.35 ± 0.88b

-4.799

-6.559

-3.038

28.544

 < 0.001

  

8.22 ± 1.19a

6.61 ± 0.98b

   
        

T0

7.50 ± 1.29

8.59 ± 1.40

6.42 ± 1.32

Time points

2

0.697

       

T1

7.15 ± 1.06

7.79 ± 1.31

6.50 ± 1.00

FACIT-Fatigue

1

0.027

       

T2

7.60 ± 1.47

8.30 ± 1.72

6.91 ± 1.41

Interaction2

2

0.676

HAQ

1.39 ± 0.14a

0.83 ± 0.12b

-0.554

-0.803

-0.304

18.947

 < 0.001

  

1.02 ± 0.16a

0.76 ± 0.13b

   
        

T0

0.81 ± 0.17

0.95 ± 0.19

0.68 ± 0.18

Time points

2

0.614

       

T1

0.86 ± 0.14

1.00 ± 0.18

0.71 ± 0.13

FACIT-Fatigue

1

0.022

       

T2

0.99 ± 0.20

1.10 ± 0.24

0.89 ± 0.18

Interaction2

2

0.907

CS-31 Total Score

94.20 ± 5.88a

59.87 ± 4.86b

-34.337

-45.278

-23.397

37.839

 < 0.001

  

72.10 ± 8.33a

57.24 ± 6.88b

   
        

T0

65.76 ± 9.17

76.13 ± 10.02

55.38 ± 9.36

Time points

2

0.545

        

T1

62.05 ± 7.21

65.61 ± 9.01

58.49 ± 6.94

FACIT-Fatigue

1

0.007

        

T2

66.21 ± 9.94

74.57 ± 11.66

57.84 ± 9.61

Interaction2

2

0.219

CS-31 Menopause and Health Domain

50.00 ± 3.08a

32.86 ± 2.55b

-17.143

-22.882

-11.405

34.284

 < 0.001

  

35.17 ± 4.08a

29.25 ± 3.21b

   
        

T0

30.45 ± 4.19

33.76 ± 4.72

27.14 ± 4.35

Time points

2

0.771

       

T1

31.83 ± 3.40

32.98 ± 4.44

30.69 ± 3.26

FACIT-Fatigue

1

0.042

       

T2

34.36 ± 4.95

38.78 ± 6.08

29.93 ± 4.70

Interaction2

2

0.385

CS-31 Psychological Domain

26.25 ± 2.46a

10.03 ± 2.03b

-16.214

-20.792

-11.636

48.180

 < 0.001

  

15.89 ± 3.41a

9.60 ± 2.76b

   
        

T0

17.52 ± 3.68

24.11 ± 4.05a

10.94 ± 3.78

Time points

2

0.060

       

T1

10.60 ± 2.92

11.48 ± 3.81b

9.71 ± 2.79

FACIT-Fatigue

1

0.008

       

T2

10.11 ± 3.94

12.09 ± 4.74a,b

8.14 ± 3.78

Interaction2

2

0.004

CS-31 Sexuality Domain

12.78 ± 1.58

12.53 ± 1.30

-0.250

-3.183

2.683

0.028

0.867

  

13.27 ± 2.29

12.29 ± 1.84

   
        

T0

11.82 ± 2.46

11.69 ± 2.73

11.95 ± 2.53

Time points

2

0.541

       

T1

12.20 ± 1.95

12.45 ± 2.51

11.96 ± 1.87

FACIT-Fatigue

1

0.530

       

T2

14.32 ± 2.68

15.66 ± 3.24

12.98 ± 2.56

Interaction2

2

0.494

CS-31 Couple Relations Domain

5.08 ± 1.46

4.49 ± 1.20

-0.591

-3.302

2.120

0.182

0.669

  

9.27 ± 1.79a

6.17 ± 1.48b

   
        

T0

6.31 ± 1.96

7.52 ± 2.13

5.10 ± 2.01

Time points

2

0.355

       

T1

8.47 ± 1.56

10.34 ± 2.06

6.59 ± 1.50

FACIT-Fatigue

1

0.008

       

T2

8.38 ± 2.05

9.95 ± 2.40

6.81 ± 1.99

Interaction2

2

0.766

CS-31 Vasomotor Subdomain

11.02 ± 1.20a

8.74 ± 0.99b

-2.279

-4.509

-0.050

4.015

0.045

  

7.28 ± 1.68a

6.80 ± 1.33b

   
        

T0

6.59 ± 1.78

6.56 ± 1.99

6.63 ± 1.85

Time points

2

0.922

       

T1

7.15 ± 1.42

7.11 ± 1.92

7.19 ± 1.36

FACIT-Fatigue

1

0.684

       

T2

7.37 ± 1.90

8.16 ± 2.36

6.58 ± 1.81

Interaction2

2

0.647

CS-31 Health Subdomain

16.75 ± 1.17a

10.42 ± 0.97b

-6.325

-8.513

-4.138

32.115

 < 0.001

  

11.30 ± 1.92a

7.91 ± 1.47b

   
        

T0

9.87 ± 1.98

12.36 ± 2.26

7.40 ± 2.06

Time points

2

0.502

       

T1

8.83 ± 1.58

9.07 ± 2.12

8.59 ± 1.51

FACIT-Fatigue

1

0.019

       

T2

10.12 ± 2.20

12.48 ± 2.84

7.76 ± 2.06

Interaction2

2

0.097

CS-31 Aging Subdomain

22.24 ± 1.74a

13.70 ± 1.44b

-8.539

-11.777

-5.301

26.721

 < 0.001

  

17.19 ± 2.25a

14.09 ± 1.85b

   
        

T0

14.29 ± 2.47

15.40 ± 2.71

13.19 ± 2.52

Time points

2

0.727

       

T1

15.66 ± 1.94

17.26 ± 2.39

14.07 ± 1.87

FACIT-Fatigue

1

0.036

       

T2

16.97 ± 2.72

18.92 ± 3.22

15.02 ± 2.62

Interaction2

2

0.765

CS-31 Aching in muscles and/or joints

4.19 ± 0.35a

3.41 ± 0.31b

-0.779

-1.394

-0.165

6.176

0.013

  

3.79 ± 0.49

3.29 ± 0.39

   
        

T0

3.33 ± 0.51

3.25 ± 0.56

3.41 ± 0.52

Time points

2

0.502

       

T1

3.40 ± 0.44

3.73 ± 0.60

3.07 ± 0.41

FACIT-Fatigue

1

0.110

       

T2

3.89 ± 0.56

4.40 ± 0.67

3.39 ± 0.53

Interaction2

2

0.057

  1. *Generalized linear models (GLzM); **General Mixed Model (GMM); Data adjusted for age, education level, income, usage time of aromatase inhibitors and body mass index. FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy—Fatigue Scale, with cut-off < 34 indicating cancer-related fatigue; Time point: T0, Baseline; T1, Intermediate period, corresponding to 12 months after T0; and T2, Final follow-up period, corresponding to 24 months after T0; PRO Instrument, Patient-Reported Outcome Instrument; HADS-A: Hospital Anxiety and Depression Scale, subscale anxiety; HADS-D: Hospital Anxiety and Depression Scale, subscale depression; HAQ, Health Assessment Questionnaire; CS-31, 31-item Cervantes Scale; SD, Standard deviation; Df, degrees of freedom. Significant Model Effects Test are in bold. Sidak test: Different superscript letters represent statistical significance when comparing pairs, p value < 0.05. 1Longitudinal phase: PRO Instruments are shown as mean ± SD; 2Interaction between FACIT-Fatigue and time points of study